ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.
ChemoCentryx, Inc.: Series D $29.9M
April 2, 2007
Leave a Comment » | 
I - Series D, R - WEST, X - IBD, X - Inflammation, X - Oncology | 
Permalink
Posted by arubenstein
